Identification and analysis of tyrosine phosphatase CD45 interacting proteins
Identification and analysis of tyrosine phosphatase CD45 interacting proteins
批准号:
09680653
负责人:
FURUKAWA Tatsuhiko
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998
中文摘要
CD 45和白细胞共同抗原相关蛋白(LAR)与大多数跨膜蛋白酪氨酸磷酸酶(RTPases)一样,在胞浆段中具有两个串联重复的酪氨酸磷酸酶结构域。从共表达的CD 3 zeta、lck和CD 45 D1CS(其828位的半胱氨酸被丝氨酸取代)的裂解物中,使用抗CD 45抗体共沉淀磷酸化的CD 3 zeta和CD 45 D1CS。这一发现表明CD 3 zeta在体内也是CD 45的良好底物。制备了三种CD 3 zeta突变体MC 1、MC 2、MC 3,它们分别含有C端第2和第3、第1和第3、第1和第2个酪氨酸残基。3种突变体均能被Ick磷酸化,但与CD 45 D1CS的亲和力几乎相同,而SHC-SH 2不能与磷酸化的MC 2结合; CD 45 D1 D2CS的1144位半胱氨酸被丝氨酸取代,与CD 3 zeta的亲和力较低,与磷酸化的CD 3 zeta的亲和力较CD 45 D1CS低。并研究了LAR与胰岛素受体(IR)的相互作用。LAR与胰岛素刺激后酪氨酸磷酸化的胰岛素受体相关并优先去磷酸化。LARD 1CS能稳定结合磷酸化IR。IR可能是LAR的生理底物,在胰岛素刺激后,LAR被IR激酶磷酸化。LARD 1D 2CS结构域1813位半胱氨酸被丝氨酸取代,与IR的亲和力较LARD ICS低,磷酸化程度较高,提示LARD 2具有自脱磷酸化活性。这些结果表明,CD 45和LAR的D1 PTP具有主要的磷酸酶活性,而D2 PTP可以独立于磷酸化而识别底物。
英文摘要
CD45 and leukocyte common antigen-related protein(LAR) have two tandem-repeated PTPase domains in the cytoplasmic segment like most of other transmembrane protein tyrosine phosphatases (RTPases). PTPase activity is associated only with the first of the two domains, PTPase domain 1(D1), and the membrane-distal PTPase domain 2(D2), which has no catalytic activity, would regulate substrate specificity.From the lysate of co-expression of CD3zeta, lck and CD45D1CS, whose cystein at 828 has replaced with serine, phosphorylated CD3zeta was coprecipitated with CD45D1CS using anti-CD45 antibody. This finding indicates CD3zeta is a good substrate of CD45 also in vivo. Three kinds mutants MC1, MC2, MC3 of CD3zeta, which are carrying only 2 tyrosine residues, 2nd and 3rd, 1st and 3rd, 1st and 2nd tyrosine from C terminus, were made. All 3 mutants can be poorly phosphorylated with Ick and has almost same affinty with CD45D1CS, but SHC-SH2 can not bind with phosphorylated MC2 mutant.CD45D1D2CS, whose cystein at 1144 was replaced with serine, has lower affinity with CD3zeta, and phsophorylated CD3zeta than CD45D1CS.Cystein of D2 has an important role of recognition of CD3zeta, independently of phosphorylation.We studied on LAR and insuline receptor (IR) interaction also. LAR was associated with and preferentially dephosphorylated the insulin receptor which was tyrosine-phosphorylated after insulin stimulation. LARD1CS can bind phosphorylated IR stably. IR can be a phsiological substrate of LAR.LAR is phsophorylated with IRkinase after insuline stimulation. LARD1D2CS , whose cystein 1813 is changed to serine in the domain 2, has lower affinity with IR and higher phosphrylation than LARDICS.These findings suggests LARD2 has auto-dephosphorylation activity. These data indicate that D1PTP of CD45 and LAR has main phosphatase activity and D2 PTP of them can recognize the substrates independently of phosphorylation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Tomoyuki Sumizawa: "Reversal of MRP-associated drug resistance by the pyridine analog, PAK-104P" Mol.Pharmacol.51. 399-405 (1997)
Tomoyuki Sumizawa:“吡啶类似物 PAK-104P 逆转 MRP 相关耐药性”Mol.Pharmacol.51。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yuji Takebayashi, Shin-ichi Akiyama, Shoji Natsugoe, Shuichi Hokita, Kiyoshi Niwa, Masaki Kitazono, Tomoyuki Sumizawa, Misako Haraguchi, Tatsuhiko Furukawa, Shuichi Nagayama and Takeshi Aikou: "The expression of multidrug resistance protein (MRP) in human
Yuji Takebayashi、Shin-ichi Akiyama、Shoji Natsugoe、Shuichi Hokita、Kiyoshi Niwa、Masaki Kitazono、Tomoyuki Sumizawa、Misako Haraguchi、Tatsuhiko Furukawa、Shuichi Nagayama 和 Takeshi Aikou:“人类多药耐药蛋白 (MRP) 的表达
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tomoyuki Sumizawa: "Reversal of MRP-associated drug resistance by the pyridine analog,PAK-104P" Molecular Pharmacology. 51. 399-405 (1997)
Tomoyuki Sumizawa:“吡啶类似物 PAK-104P 逆转 MRP 相关耐药性”分子药理学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Zhe-Sheng Chen: "An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells" Experimental Cell Research. (発表予定). (1998)
Zhe-Sheng Chen:“抗顺铂人类 KB 癌细胞中重金属的主动外排系统”实验细胞研究(即将发表)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yutaka Chuman: "Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximide in combination with PAK-104P" Cancer Lett.129. 69-76 (1998)
Yutaka Chuman:“通过丁硫氨酸亚磺酰亚胺与 PAK-104P 组合逆转 KB 细胞中 MRP 介导的长春新碱耐药性”Cancer Lett.129。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 35 条
Analysis of cooperative functions of transporters andvesicle transport system in efflux of anticancer agents
-
批准号:22501047
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2010
-
负责人:FURUKAWA Tatsuhiko
-
依托单位:
Nano-scale analysis of the drug transport mechanism of MRP1
-
批准号:17590272
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2005
-
负责人:FURUKAWA Tatsuhiko
-
依托单位:
Analysis of substrates transport mechanism and structural modification of MRP1
-
批准号:14570123
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2002
-
负责人:FURUKAWA Tatsuhiko
-
依托单位:
Analysis of the mechanisms for biological activities of thymidine phosphorylase
-
批准号:12670144
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2000
-
负责人:FURUKAWA Tatsuhiko
-
依托单位:
国内基金
海外基金
登录
查看更多内容
循环肿瘤细胞通过获得CD45逃避T细胞的抗肿瘤免疫及促进肿瘤转移的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:王雪萍
-
依托单位:
TGF-β降解TAL1在EPOR缺失导致荷瘤状态下CD45阳性红系前体细胞分化阻滞中的作用及机制
-
批准号:81972699
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:龙海霞
-
依托单位:
CD45 PTPs对脓毒症T细胞亚群分化调控机制及黄芪皂苷干预作用的研究
-
批准号:81960745
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2019
-
负责人:万春平
-
依托单位:
反义非编码RNA调控淋巴细胞CD45亚型表达的研究
-
批准号:31870745
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:苏中静
-
依托单位:
靶向CD45调节T细胞分化及自身免疫
-
批准号:2018JJ2351
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2018
-
负责人:练高建
-
依托单位:
骨髓单个核细胞中CXCR4(+)CD45(-)细胞群对慢性脑缺血的治疗作用及机制研究
-
批准号:81701162
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:李楠
-
依托单位:
黄芪皂苷调控CD45蛋白酪氨酸磷酸酯酶介导抗肿瘤免疫分子机制的研究
-
批准号:81460624
-
项目类别:地区科学基金项目
-
资助金额:50.0万元
-
批准年份:2014
-
负责人:万春平
-
依托单位:
CD45及剪接变构体在骨髓造血干细胞层面始动银屑病发病的机制研究
-
批准号:81171507
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:刘晓明
-
依托单位:
cd45途径NK细胞激活的细胞内信号传递研究
-
批准号:39770694
-
项目类别:面上项目
-
资助金额:12.0万元
-
批准年份:1997
-
负责人:沈锋
-
依托单位: